HPTN 083
id:
hptn-083-295-15957135
title:
HPTN 083
text:
HPTN 083 is a 2016 clinical trial which compares cabotegravir injections with oral use of Emtricitabine/tenofovir as pre-exposure prophylaxis ("PrEP") for prevention of HIV/AIDS. The study seeks to test injectable PrEP as a way to remedy adherence for many patients on a daily pill regimen. HPTN 083 is the first large scale phase III clinical trial of cabotegravir. In February 2016 researchers presented the results of the ECLAIR study. That study examined cabotegravir and found no serious safety
brand slug:
wiki
category slug:
encyclopedia
description:
2016 clinical drug trial
original url:
https://en.wikipedia.org/wiki/HPTN_083
date created:
date modified:
2023-09-27T03:57:59Z
main entity:
{"identifier":"Q28868647","url":"https://www.wikidata.org/entity/Q28868647"}
image:
fields total:
13
integrity:
14